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Abstract: The management of mitral valve regurgitation (MR), a common valve disease, represents 
a challenge in clinical practice, since the indication for either surgical or percutaneous valve 
replacement or repair are guided by symptoms and by echocardiographic parameters which are not 
always feasible. In this complex scenario, the use of natriuretic peptide (NP) levels would serve as 
an additive diagnostic and prognostic tool. These biomarkers contribute to monitoring the 
progression of the valve disease, even before the development of hemodynamic consequences in a 
preclinical stage of myocardial damage. They may contribute to more accurate risk stratification by 
identifying patients who are more likely to experience death from cardiovascular causes, heart 
failure, and cardiac hospitalizations, thus requiring surgical management rather than a conservative 
approach. This article provides a comprehensive overview of the available evidence on the role of 
NPs in the management, risk evaluation, and prognostic assessment of patients with MR both before 
and after surgical or percutaneous valve repair. Despite largely positive evidence, a series of 
controversial findings exist on this relevant topic. Recent clinical trials failed to assess the role of 
NPs following the interventional procedure. Future larger studies are required to enable the 
introduction of NP levels into the guidelines for the management of MR. 
Keywords: natriuretic peptides; mitral valve regurgitation; valve repair; valve replacement; risk 
prediction 
 
1. Introduction 
Mitral regurgitation (MR) represents one of the most frequent valve diseases with an indication 
for valve replacement or repair, both as surgical or transcatheter interventional management [1]. 
The etiology of mitral dysfunction, namely primary or secondary regurgitation, should be 
clearly identified. In primary or organic MR, the valve apparatus is directly affected as a consequence 
of a degenerative (i.e., fail leaflet or prolapse) or infective (i.e., endocarditis) process. In secondary or 
functional MR, the structure of the components of the valve apparatus, such as leaflets and chordae, 
is preserved, but an impaired left ventricular (LV) geometry is responsible of an altered balance 
between closing and tethering forces on the valve. In both abovementioned conditions, MR is 
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responsible for or contributes to the development of LV and left atrial (LA) overload, leading to 
hemodynamic alterations. 
According to the most recent European Guidelines [2], urgent surgery is recommended in cases 
of acute severe MR. In chronic primary MR, valve replacement or repair is indicated in symptomatic 
patients and, in the absence of symptoms, in the presence of LV ejection fraction (LVEF) <60%, LV 
end-systolic diameter (LVESD) ≥45 mm, atrial fibrillation (AF), and systolic pulmonary pressure ≥50 
mmHg. Valve repair should be preferred if feasible and able to achieve a durable result with a low 
risk of re-intervention, such as in segmental valve prolapse. Rheumatic lesions, leaflets, or extensive 
annular calcifications more often require valvular replacement, preferably preserving sub-valvular 
apparatuses. In patients with high surgical risk, percutaneous edge-to-edge mitral repair is currently 
widely adopted and recommended by international Guidelines [2,3]. 
In secondary MR, due to significant operative mortality, high rates of recurrent MR, and the 
absence of a definite survival benefit, surgery is indicated when concomitant coronary 
revascularization is required. Even in this circumstance, percutaneous edge-to-edge repair may 
represent an efficacious option [4,5]. 
Although a “watchful waiting” strategy is considered safe and is accepted in asymptomatic 
patients, the assessment of correct and univocal timing of surgeries still remains a challenge. The 
identification of symptoms may be difficult due to its subjective nature and to the risk that patients 
could minimize their clinical manifestations in order to delay surgery, or could progressively reduce 
their activities as a consequence of an impaired functional capacity. In addition, symptoms may 
become clear when LV dysfunction is irreversible [6]. 
In this complex scenario, one of the unmet needs is a more accurate risk stratification, in which 
biomarkers may represent a useful tool to identify patients with a possibly unfavorable prognosis 
under conservative management or after mitral valve (MV) surgery. 
Among several biomarkers available in clinical practice, natriuretic peptides (NPs) have a well-
established role in cardiovascular diseases and, particularly, in heart failure (HF) where they reflect 
cardiac overload, LV systolic and diastolic dysfunctions, and are associated to cardiovascular 
outcomes [7]. 
Atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP), and their inactive N-terminal 
portions (NT-proANP and NT-proBNP) are released in response to increased myocardial stretch, as 
a consequence of volume or pressure overload. NPs exert several cardiovascular and renal actions 
mediated by the type A natriuretic peptide receptor through the second messenger cGMP. The effects 
of NPs are able to counterbalance hemodynamic congestion through the regulation of electrolytes, 
water balance, and permeability of systemic vasculature. Moreover, they inhibit the renin–
angiotensin–aldosterone system and the sympathetic nervous system. At the cellular level, a 
modulatory role on cellular growth and proliferation is recognized [8–10]. Some differences exist 
among NPs. ANP is stored in granules as a previously synthesized pool within the atrial 
cardiomyocytes and is quickly released upon request. BNP production is regulated by gene 
expression in ventricular cardiomyocytes, secreted as a prohormone, then cleaved into the active 
peptide and the NT-proBNP. As compared to ANP, BNP has a longer half-life (1–2 hours compared 
to approximately 22 minutes) and greater plasma concentrations (about 10-fold higher) [11,12]. 
Moreover, it has been proposed that NPs’ responses may depend on the specific pathophysiology of 
the underlying cardiac stress, suggesting that ANP may be more sensitive in the case of subclinical 
damage, whereas the BNP level shows a greater increase in acute conditions [13,14]. 
The aim of our review is to analyze the current available evidence on the role of NPs in the 
management, risk evaluation, and prognostic assessment of patients with MR before and after 
surgical or percutaneous valve repair. 
2. NPs and Risk Assessment in MR 
Several studies have investigated the association between increased levels of NPs in patients 
with MR, parameters of LV dysfunction, and cardiovascular outcomes. 
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An analysis of data obtained in 1399 patients from 15 studies found a positive relationship 
between levels of NPs and LV end-systolic parameters, such as the LV end-systolic index (LVESI) 
and LVESD [15]. BNP level was also associated with the myocardial performance index (MPI), an 
echocardiographic index of systolic and diastolic function [16]. Mayer and colleagues documented 
that patients with severe MR and BNP values >409 pg/mL had a mean LVESD of 40 mm [17], which 
represents a criterion for surgery according to U.S. Guidelines [3]. A linear relationship between the 
LVESD value of 40 mm and NT- proBNP level >292 pg/mL was identified by Potocki et al. [18]. An 
elevated BNP level has been documented in patients with pulmonary artery pressure >50 mmHg [18], 
this parameter being another indication for valve replacement or repair [2,3]. NT-proBNP values 
were directly related to HF functional classes in MR, with mean levels of 97 pg/mL for New York 
Heart Association (NYHA) class I, 170 pg/mL for class II, and 458 pg/mL for class III [19]. The addition 
of BNP to the Society of Thoracic Surgeons (STS) score improved the risk stratification in patients 
with primary MR and preserved LVEF [20]. 
In a prospective study conducted in 124 patients with chronic primary MR, Detaint and 
colleagues analyzed the relationship between BNP level, MR degree, LV and LA remodeling, and 
prognosis [21]. BNP level was associated to the LV end-systolic volume index, LA volume, and 
symptoms, and it was able to predict prognosis independently from age, sex, functional class, MR 
severity, and LVEF. At the 5-year follow-up, survival was significantly worse in patients with BNP 
level >31 pg/mL, showing a higher incidence of the combined end-point of death and HF [21]. 
In another study, BNP level >105 pg/mL had stronger predictive power compared to the most 
common parameters of MR severity, such as an effective orifice regurgitant area (EROA) and LVESD 
[22]. In 49 patients with MR and preserved ejection fraction (>55%), BNP >41 pg/mL and NT-
proBNP>173 pg/mL showed the best accuracy in predicting the development of symptoms [23]. In 87 
patients with severe MR, BNP below 80 pg/mL and NT-proBNP lower than 200 pg/mL showed the 
greatest negative predictive value of 98% for the development of symptoms or LV dysfunction during 
follow-up [24]. 
The prognostic role of BNP level in the management of MR has also been examined during 
exercise. 
Exercise BNP level was strongly correlated with those measured at rest [25]. Patients with higher 
BNP values showed more severe MR, greater LA volume, more elevated systolic pulmonary 
pressure, and LV filling pressure estimated as an E/e’ ratio. Moreover, detected exercise BNP levels 
were higher in patients who developed symptoms and had an increased incidence of cardiac events, 
independently from age, gender, and body mass index. In patients with moderate MR, only the 
exercise LV global longitudinal strain, but neither resting nor exercise LVEF, was an independent 
determinant of exercise BNP level. A plausible explanation of these findings is that the BNP level has 
been assessed in patients with degenerative MR and not in MR secondary to LV dilatation, in which 
levels of NPs were measured before the development of LV systolic dysfunction [25]. A cut-off of 64 
pg/mL was identified as the best cut-off value for exercise BNP level to behave as an independent 
predictor of worse cardiovascular outcomes [25]. Other studies have consistently demonstrated that 
an increase in BNP level during exercise is related to the development of HF, to subclinical LV 
dysfunction, and to reduced performance capacity [26,27]. 
According to the abovementioned results, BNP level may be used in clinical practice as a 
complementary tool for echocardiographic exams and exercise tests in order to identify those patients 
who are more likely to experience death from cardiovascular causes, and HF and cardiac 
hospitalizations, thus requiring surgical management, rather than a conservative approach. In 
addition, NPs may represent an essential tool to monitor the progression of the valve disease before 
the development of hemodynamic consequences in a preclinical stage of myocardial damage. 
However, some controversial aspects deserve to be better-clarified. First of all, as documented 
by the abovementioned studies, it is still difficult to establish a univocal cut-off level able to identify 
MR patients at elevated cardiovascular risk, since different levels of NPs have been identified in the 
different studies. To overcome this problem, Clavel et al. introduced the BNP ratio, which is derived 
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from a measured BNP value divided by the expected value related to the age and sex of each patient 
[26]. 
This parameter behaves as a significant independent prognostic marker of outcomes in valve 
heart disease patients, including MR patients under medical treatment [28,29]. However, it failed to 
maintain its role after surgery [28]. Interestingly, the BNP/ANP ratio revealed a prognostic role in 
one study, being significantly higher in the presence of clinical and echocardiographic criteria used 
for surgery recommendation, such as LVESD ≥45 mm, LVEF ≤60%, NYHA class II or greater, and AF 
[30]. 
Other critical issues relate to the appropriate time interval that should be considered for the 
subsequent measurements of the NP level, and the magnitude of changes of NP values between 
baseline and subsequent assessments, which may be related to a poor clinical outcome. In addition, 
age, AF, renal function, and body weight are known modulators of NP levels, thus representing 
potential confounders [31]. Finally, since a high BNP level may also be detected in patients with 
moderate MR, it cannot be used as a surrogate for MR quantification. On the other hand, it should be 
pointed out that, in the presence of good hemodynamic compensation with a normal NP level, 
regardless of LV dimension, the need for an interventional strategy may be missed. 
3. The Role of NPs to Predict Outcome after MV Surgery or Percutaneous Repair 
During the last few years, percutaneous edge-to-edge MV repair with the MitraClip (Abbott 
Vascular, CA USA) device has acquired increasing importance as a treatment option, especially in 
patients with HF with an elevated surgical risk. However, many patients are still being treated with 
the surgical MV repair or replacement, which represents the gold-standard procedure. Apart from 
the reduction of MR, both percutaneous and surgical interventions may produce several 
hemodynamic benefits, reducing LV and LA pressure and volume overload and, as a consequence, 
the myocardial wall stretch [2,3]. 
In this context, several studies have assessed the role of NPs in the management of patients 
treated with MV repair or replacement, investigating the sensibility of these biomarkers in identifying 
subjects with a worse response to the performed interventional procedure and with a lower chance 
of survival. 
In a study involving 65 patients treated with edge-to-edge valve repair, a low NT-proBNP level, 
measured 6 months after the procedure, was associated with a significant reduction in LV end-
diastolic volume (LVEDV) and end-systolic volume (LVESV) and to an improvement in LV and LA 
longitudinal strain [32]. Worse renal function, larger LVEDV, and a higher transmitral gradient after 
MitraClip (Abbott Vascular, CA USA) implantation were independently associated with a higher 
level of NT-proBNP at follow-up. Patients with low and medium NT-proBNP tertiles experienced a 
significantly greater reduction in NYHA functional class symptoms and quality of life score 
compared to those with a higher NT-proBNP level. At the 6-month follow-up, successful MR 
reduction was observed in a higher number of patients with low and medium NT-proBNP tertiles, 
whereas severe MR more often persisted in the high NT-proBNP tertile group (43%) [32]. 
After percutaneous valve repair, improvements in 6-minute walking distances and a decrease 
in LV volumes were paralleled by a significant reduction of NT-proBNP level [33]. 
Hwang and colleagues identified a BNP cut-off level of 125 pg/mL associated with a higher risk 
of cardiac death and re-hospitalization for cardiac causes in 117 patients who underwent surgical MV 
replacement [34]. Interestingly, a study conducted with 44 patients treated with transcatheter valve 
repair, as well as baseline levels of mid-regional proANP and NT-proBNP were significantly higher 
in those who experienced death or re-hospitalization for HF during a median follow-up of 211 days 
[35]. In a cohort of 174 retrospectively examined patients, the NT-proBNP level was significantly 
associated to survival at univariate analysis, but the independent predictive power of NT-proBNP 
was not confirmed at multivariate analysis [36]. However, the post-operative NT-proBNP level 
maintained its predictive role for a clinical outcome at multivariate analysis in other studies [37–39]. 
As for the pre-operative level, controversial findings were frequently reported with regard to 
the post-operative level. In 59 patients who underwent percutaneous MV repair, achieving a 
J. Clin. Med. 2020, 9, 1348 5 of 12 
 
reduction of MR, an improvement of functional class, and structural reverse cardiac remodeling 
(reduced LA volume and LVESD and increased LVEF), the NT-proBNP level did not decrease 
significantly [40]. Similar findings were provided by Yoon et al. in a cohort of 144 patients 
successfully treated with edge-to-edge repair, in which the NT-proBNP level did not significantly 
decrease after MV clipping. In addition, NT-proBNP changes were not related to baseline LVEF and 
LV diameter and were not able to predict cardiovascular outcomes during a 6-month follow-up [41]. 
Furthermore, in a study which enrolled 194 patients treated with percutaneous valve repair, the NT-
proBNP level remained elevated (≥10,000 pg/mL) in those patients who achieved a reduction of MR 
to grade ≤2 (21%) [42]. These controversial results may be explained by differences in the sample size 
of the enrolled populations, in the characteristics of the included patients (baseline LVEF, pulmonary 
artery pressure, LV diameter and diastolic function), in the duration of the follow-up, and also the 
rhythm status (i.e., sinus rhythm or AF) [43]. 
Finally, as for the pre-surgical management, it has not been clearly established which biomarker 
should be chosen, which cut-off value should be considered for the risk assessment of the patients, 
and which interval for serial monitoring of NPs has the best accuracy. 
4. NPs Levels in MITRA-FR and COAPT Trials 
Two recent trials have become available in patients subjected to MV repair. The MITRA-FR 
(Percutaneous Repair with the MitraClip Device (Abbott Vascular, CA USA) for Severe 
Functional/Secondary Mitral Regurgitation) trial, conducted in patients with severe secondary MR, 
showed that percutaneous MV repair added to standard pharmacological therapy was unable to 
reduce the rate of death or unplanned hospitalizations for HF at 1 year compared to those who 
received medical therapy alone [44]. 
The Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart 
Failure Patients with Functional Mitral Regurgitation (COAPT) study demonstrated that the 
transcatheter MV repair reduced the rate of hospitalizations for HF and all-cause mortality within 12 
and 24 months of follow-up [45]. Although the MITRA-FR and COAPT trials enrolled comparable 
populations of patients with secondary MR, they obtained diametrically opposed results [44,45]. 
Several possible mechanisms have been proposed to explain the discrepant findings, mostly 
focusing on the different echocardiographic characteristics of the subjects included in the two trials 
[46,47]. The COAPT excluded patients with very severe LV dilation (LVESD <70mm), whereas LV 
diameter did not represent an exclusion criterion in MITRA-FR. This resulted in a significant 
difference in the documented mean LV volume (LVEDV 135 ± 35mL/m2 in MITRA-FR vs. 101 ± 
34mL/m2 in COAPT) [44–47]. More interestingly, the two populations had a different degree of MR, 
the EROA being significantly greater in COAPT as compared with MITRA-FR (41 ± 15 mm2 vs. 31 ± 
10 mm2, respectively) [44–47]. According to these considerations, it has been supposed that the 
underlying cardiac disease was probably the main cause of HF and the determinant of prognosis in 
MITRA-FR, with MR being a marker of adverse LV remodeling. In contrast, the LV dysfunction was 
more related to MR severity in COAPT, which also represented the main contributor to outcomes 
[48]. In such a context, it has been proposed that the degree of MR was “proportionate” to the degree 
of LV dilatation in MITRA-FR, whereas it was “disproportionate” in COAPT, and this parameter may 
have influenced the different clinical response to the percutaneous repair procedure [46,47]. 
In this complex scenario, the differences in the baseline NP levels between the two studies may 
mirror the different pathophysiological mechanisms. In the COAPT trial, both NT-proBNP and BNP 
levels were significantly higher than in MITRA-FR (median NT-proBNP > 5100 vs. 3200 pg/mL and 
median BNP >1000 vs. >760 pg/mL, respectively), and it may be argued that they were more related 
to MR severity than to either LVEF or LV diameter [44,45]. In fact, a higher degree of MR may have 
produced an increase in atrial and ventricular loading conditions, leading to a higher NP level. 
Unfortunately, precise data about the LA dimension, diastolic function (i.e., assessed with E/e’ ratio), 
and systolic pulmonary pressure were not provided in the two trial populations. Furthermore, the 
two studies did not obtain any information about overtime changes in NPs levels after the 
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transcatheter MV repair procedure. Therefore, their potential relationship to echocardiographic 
parameters and to clinical outcomes could not be assessed in these trials. 
5. NPs and Other Biomarkers 
The most plausible pathophysiological explanation for the better association of NPs with pre- 
and post-procedural outcomes may be their optimal capacity to reflect cardiac performance in 
different hemodynamic conditions. Of note, lack of a sufficient number of studies using ANP as a 
marker in the management of MR does not currently allow to make a robust comparison with BNP. 
Several efforts have been made over the last few years to investigate the role of other biomarkers 
in the MR condition, and have been previously reviewed [49]. More recently, other biomarkers have 
been investigated with some interesting insights. 
The neutrophil gelatinase-associated lipocalin (NGAL) and cystatin C, both markers of 
functional and structural kidney damage, were shown to predict mortality in high-risk patients 
undergoing percutaneous MV repair [50]. However, they had low accuracy, probably due to a lack 
of relationship with the hemodynamic balance [35]. Similarly, the highly sensitive C-reactive protein 
(hsCRP), a biomarker able to improve risk prediction for cardiovascular diseases, showed low 
performance in the prognostic assessment of the MR patients [35]. On the other hand, the pre-
operative level of soluble ST-2, a member of the interleukin-1 receptor family previously described 
as a stronger biomarker of myocardial stretch in HF, was correlated with LV function and structure 
after MV repair, thus providing complementary prognostic information to NT-proBNP level [35]. The 
level of galectin-3, a well-established marker of LV fibrosis, has been associated with worse 
cardiovascular outcomes after MV repair [35]. Interestingly, low galectin-3 and ST2 plasma levels 
were predictors of therapeutic success in 210 patients treated with percutaneous MV repair (PMVR) 
[51]. Of note, a lower galectin-3 level was a predictor of MR improvement after cardiac 
resynchronization therapy (CRT) [52]. In addition, biomarkers reflecting inflammation (hsCRP, 
interleukin-6) and cardiac remodeling processes (matrix metalloproteinases (MMP-2 and MMP-9)) 
were associated with a higher risk of mortality following the procedure [53]. The highly sensitive 
troponin T showed strong prognostic power in predicting survival after transcatheter MV repair, 
with an accuracy comparable to that of a mid-regional proANP level [35]. 
Of note, some evidence of the role of other parameters in the outcome prediction of MR patients 
has been collected. For instance, it was found that abnormalities of the calcium-phosphate 
metabolism may influence the health-related quality of life in patients with severe MR [54]. 
Amelioration of oxidative stress and endothelial dysfunction may be indicators of successful MV 
repair in patients with MV prolapse [55]. 
Finally, one study reported the negative prognostic impact of pre-procedural anemia in patients 
who underwent PMVR with a higher baseline NT-proBNP level [56]. 
Based on the evidence collected so far, markers of mechanisms involved in the cardiac 
remodeling process may be considered as complementary prognostic tools to the NP level. 
6. Conclusions 
The management of MR still represents a real challenge for physicians, since the assessment of 
symptoms is difficult and the recommended diagnostic exams, such as the echocardiogram, are often 
not accurately performed. It is well-known that NP secretion occurs in the presence of atrial and 
ventricular stretch, as a consequence of pressure and volume overload, and that NPs are independent 
predictors of mortality and morbidity in patients with severe MR. Due to their feasible measurement 
and to their significant association with echocardiographic parameters of LV dysfunction and of 
impaired filling, these biomarkers may represent an important tool to identify patients at elevated 
risk of adverse clinical outcomes, in which early surgical or percutaneous intervention should be 
considered (Figure 1 and Figure 2). 
Moreover, the NP level has also been documented to be a powerful independent predictor of 
reduced cardiac event-free survival in patients treated with surgical or transcatheter valve repair or 
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replacement, thus representing potential instruments to significantly improve the evaluation of a 
short- and long-term prognosis after these procedures. 
Although some controversies still exist, the majority of findings discussed in our review article 
are encouraging, and indicate NPs as potentially useful biomarkers for the clinical management of 
MR. Further larger studies are needed to solve key issues, that is, to better define which biomarker 
should preferably be used among NPs, which rest and eventually stress cut-off levels could clearly 
identify high-risk patients, and which degree of variation between serial measurements may have 
the best clinical accuracy. It is hoped that these future studies will allow the introduction of NP levels 
into the guidelines for the management of MR. 
 
Figure 1. Summary of the main topics discussed in this review. Abbreviation legends: CV = 
cardiovascular; MR = mitral regurgitation; MV = mitral valve; NPs = natriuretic peptides. 
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Figure 2. Main clinical implications of NPs in MR. Abbreviation legends: HF = Heart failure; LA = left 
atrium; LV = left ventricle; NPs = natriuretic peptides; PMVR = percutaneous mitral valve repair. 
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